Skip to main content
. 2021 Jan 20;42(10):1620–1629. doi: 10.1038/s41401-020-00590-4

Fig. 3. Early-life fingolimod treatment inhibits the activation of colonic TLR2/4-NF-κB-NLRP3 in diabetes-prone NOD mice.

Fig. 3

Mice were treated daily with 1 mg/kg fingolimod in 100 µL sterile water or an equal volume of sterile water by gavage from weaning. Colonic tissue was collected from 12-week-old mice. Western blot analysis of colonic TLR2, TLR4, p-P65, NLRP3, p20, and IL-1β expression and gray value analysis by ImageJ. The data are the mean ± SEM (n = 4 experiments with two pooled mice in each experiment/group). *P < 0.05 versus Con, **P < 0.01 versus Con.